Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?
Despite the benefits of hormonal therapy (HT) adherence remains suboptimal in ER positive breast cancer patients. Medication adherence is challenging to assess and tends to be overestimated. The Digital Health Feedback System (DHFS) consists of an ingestible sensor attached to a pill that sends intake date and time to a smart phone or computer. Patients can share this information with health care providers and other persons. The DHFS can also send reminders. This mixed methods study examined providers’ perceptions of HT medication adherence. The potential role of the DHFS in enhancing medication tracking and adherence was also explored. We conducted semi-structured interviews with key informants (N = 10). Questions examined perceptions about adherence barriers and facilitators, challenges tracking adherence, and views on the DHFS. Findings informed the development of a survey that was administered online (N = 19). Providers emphasized the importance of fostering open and trustful communication around adherence. The most mentioned challenges to assessing adherence were the patient not disclosing discontinuation immediately (78.9%) and over-reporting adherence (57.9%). The perceived potential benefits of DHFS were the ability to track adherence better (94.7%) and reminders to take the medication (68.4%). Safety to ingest a sensor was a major perceived barrier (8 4.2%). Interventions that target providers and doctor-patient communication are warranted to enhance adherence and reduce communication delays around HT discontinuation. DHFS has the potential to enhance HT adherence by directly targeting barriers. Future studies should also examine the feasibility of adopting the DHFS with cancer patients.
KeywordsPatient-doctor communication Hormonal therapy adherence Digital health feedback system
The project described was supported by the National Cancer Institute (Sheppard: PI, grant number: R01CA154848). This project was also supported by the Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) by Federal Funds, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA) (Award Numbers: KL2TR001432; PI Hurtado de Mendoza) and Georgetown University Internal Grant (‘Reflective Engagement for the Public Interest’, MPIs Sheppard and Hurtado-de-Mendoza). The content is solely responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Science, the National Institute of Health.
Compliance with ethical standards
The study was approved by Georgetown University Institutional Review Board.
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures in this study have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable standards.
- 1.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.CrossRefGoogle Scholar
- 11.Rivero-Mendez M, Dawson-Rose CS, Solis-Baez SS. A qualitative study of providers' perception of adherence of women living with HIV/AIDS in Puerto Rico. Qual Rep. 2010;15:232.Google Scholar
- 15.Kane JM, Perlis RH, DiCarlo LA, Au-Yeung K, Duong J, Petrides G. First experience with a wireless system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder. JClinPsychiatry. 2013;74:533.Google Scholar
- 18.SocioCultural Research Consultants L. Dedoose Version 7.0.23, web application for managing, analyzing, and presenting qualitative and mixed method research data 2016.Google Scholar
- 19.Ayres LR, Baldoni ADO, De Sa Borges AP, Pereira LRL. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. IntJClinPharm. 2014;36:45–54.Google Scholar
- 30.Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. AnnOncol. 2012;23:882–90.Google Scholar
- 31.Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. The Journal of Supportive Oncology. 2007;5:139.Google Scholar
- 37.Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, et al. Bidirectional text messaging to monitor endocrine therapy adherence and patient-reported outcomes in breast Cancer. JCO Clinical Cancer Informatics. 2017;(1):1–10.Google Scholar
- 40.Ramsey RR, Zhang N, Modi AC. The stability and influence of barriers to medication adherence on seizure outcomes and adherence in children with epilepsy over 2 years. J Pediatr Psychol. 2017.Google Scholar
- 43.The Canadian Interprofessional Health Collaborative, (CIHC). A National Interprofessional Competency Framework 2010.Google Scholar